Sterling Investment Advisors (Pennsylvania)’s Oramed Pharmaceuticals ORMP Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,150	Closed	-$14K	–	374
2022 Q2	$14K	Hold	3,150	–	–	﹤0.01%	365
2022 Q1	$27K	Hold	3,150	–	–	0.01%	330
2021 Q4	$45K	Hold	3,150	–	–	0.01%	268
2021 Q3	$69K	Hold	3,150	–	–	0.02%	222
2021 Q2	$42K	Hold	3,150	–	–	0.01%	277
2021 Q1	$32K	Hold	3,150	–	–	0.01%	275
2020 Q4	$13K	Hold	3,150	–	–	﹤0.01%	345
2020 Q3	$8K	Hold	3,150	–	–	﹤0.01%	362
2020 Q2	$11K	Hold	3,150	–	–	﹤0.01%	340
2020 Q1	$9K	Hold	3,150	–	–	﹤0.01%	323
2019 Q4	$16K	Hold	3,150	–	–	0.01%	315
2019 Q3	$10K	Hold	3,150	–	–	0.01%	341
2019 Q2	$11K	Hold	3,150	–	–	0.01%	344
2019 Q1	$11K	Hold	3,150	–	–	0.01%	337
2018 Q4	$9K	Hold	3,150	–	–	0.01%	337
2018 Q3	$15K	Hold	3,150	–	–	0.01%	329
2018 Q2	$23K	Hold	3,150	–	–	0.01%	283
2018 Q1	$21K	Hold	3,150	–	–	0.01%	273
2017 Q4	$28K	Hold	3,150	–	–	0.02%	238
2017 Q3	$31K	Hold	3,150	–	–	0.02%	225
2017 Q2	$24K	Hold	3,150	–	–	0.02%	240
2017 Q1	$19K	Hold	3,150	–	–	0.01%	252
2016 Q4	$19K	Buy	+3,150	New	+$20.5K	0.02%	224

Other funds holding ORMP

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s ORMP Position: Q3 2022 in Review

Sterling Investment Advisors (Pennsylvania) sold out of Oramed Pharmaceuticals (ORMP) in Q3 2022, closing a stake of 3,150 shares — an estimated $14K sold.

Sterling Investment Advisors (Pennsylvania) first reported a position in ORMP in Q4 2016 and held it in 23 quarters. The position peaked at $69K in Q3 2021. 71 funds tracked by Wall St. Rank hold ORMP as of Q3 2022.

Sterling Investment Advisors (Pennsylvania) reported no remaining Oramed Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Sterling Investment Advisors (Pennsylvania) sold 3,150 Oramed Pharmaceuticals shares in Q3 2022, an estimated $14K.
Sterling Investment Advisors (Pennsylvania) first reported a position in Oramed Pharmaceuticals in Q4 2016 and held it in 23 quarters.
Sterling Investment Advisors (Pennsylvania)'s Oramed Pharmaceuticals position peaked at $69K in Q3 2021.
71 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2022.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q3 2022, filed 3 Nov 2022.